You are here

Generic Version of Zoloft Receives Tentative Approval

FORT LEE, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE:ALO) , a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted tentative approval for the company's ANDA for sertraline hydrochloride 25 mg, 50 mg, and 100 mg tablets. Alpharma's sertraline hydrochloride tablets are the AB-rated generic equivalent of Pfizer's Zoloft(R) tablets, a product indicated for several disorders, including depression. Zoloft(R) tablet sales in 2004 were approximately $3 billion.

This tentative approval was received by the company's U.S. Generic business. On October 17, 2005, the company announced that it had reached a definitive agreement to sell both its U.S. and International Generics businesses to Actavis Group.

Source: Alpharma, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs